{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-024375","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2026-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.656187+00:00","generated_at":"2026-05-16T07:27:08.315920+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Cardiff Oncology CEO and CFO step down; onvansertib Phase 2 hits 72.2% ORR in mCRC","bullets":["CEO Mark Erlander and CFO James Levine stepped down; Mani Mohindru named interim CEO, Brigitte Lindsay promoted to CAO.","Phase 2 CRDF-004: onvansertib 30mg + FOLFIRI/bev showed 72.2% ORR vs 43.2% SoC (p=0.051) and PFS HR 0.37 vs SoC (p=0.048).","Company selected 30mg dose of onvansertib with FOLFIRI/bev for registrational program; plans to initiate later in 2026 after FDA consultation.","Final data and registrational plans expected in H1 2026; onvansertib well-tolerated with no additive toxicity.","Conference call today at 8:30 a.m. ET to discuss results and strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-024375","json":"https://secwatch.observer/filing/0001193125-26-024375.json","markdown":"https://secwatch.observer/filing/0001193125-26-024375.md","text":"https://secwatch.observer/filing/0001193125-26-024375.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526024375/0001193125-26-024375-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526024375/crdf-20260127.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T07:27:08.315920+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}